MARAVAI LIFESCIENCES HOLDINGS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 09/30/24 | FY 06/30/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $185.7M | $259.2M | — | — | $288.9M |
| Cost of revenue | $151.8M | $150.9M | — | — | $148.7M |
| Gross profit | $34.0M | $108.3M | — | — | $140.2M |
| Selling, general & administrative | $145.1M | $161.8M | — | — | $151.4M |
| Research and development | $17.4M | $19.2M | — | — | $17.3M |
| Operating income | -$215.3M | -$235.6M | — | — | -$31.6M |
| Interest expense | $27.0M | $47.7M | — | — | $45.9M |
| Pretax income | -$235.0M | -$261.5M | — | — | $617.7M |
| Income tax expense | -$4.2M | -$1.9M | — | — | $756.1M |
| Net income | -$130.8M | -$144.8M | — | — | -$119.0M |
| Balance Sheet | |||||
| Cash and equivalents | $216.9M | $322.4M | $578.2M | $573.2M | $575.0M |
| Current assets | $296.3M | $429.1M | $679.1M | $681.5M | $699.9M |
| Total assets | $770.6M | $1.0B | $1.3B | $1.4B | $1.5B |
| Current liabilities | $44.9M | $57.0M | $63.7M | $68.6M | $87.5M |
| Total liabilities | $397.9M | $431.0M | $665.6M | $671.3M | $697.6M |
| Total debt | $294.2M | $299.7M | — | — | $533.1M |
| Stockholders' equity | $212.4M | $325.3M | $344.9M | $434.7M | $416.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$57.6M | $7.5M | — | — | $126.2M |
| Depreciation and amortization | $23.6M | $20.9M | — | — | $12.9M |
| Stock-based compensation | $30.2M | $49.4M | — | — | $34.6M |
| Capital expenditure | $13.1M | $29.7M | — | — | $65.6M |
| Free cash flow | -$70.7M | -$22.2M | — | — | $60.7M |
| Impairments | $84.6M | $166.2M | — | — | $0 |
Shares outstanding 258.2M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.